Related Experiment Video
Updated: Jul 19, 2025
08:46
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
53.4K
Chimeric Antigen Receptor T Cells in Multiple Myeloma
1Department of Hematology, Dartmouth Cancer Center, 1 Medical Center Drive, Lebanon, NH 03750, USA; Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02115, USA.
Hematology/Oncology Clinics of North America
|August 10, 2023
Summary
Chimeric antigen receptor (CAR) T-cell therapy has revolutionized multiple myeloma treatment. This review examines current CAR T-cell therapy and future treatment targets for this hematological malignancy.
Area of Science:
- Hematology
- Immunotherapy
- Oncology
Background:
- Multiple myeloma is a significant hematological malignancy, affecting approximately 8.5 per 100,000 individuals annually.
- Recent therapeutic advancements have transformed multiple myeloma management.
- Chimeric antigen receptor (CAR) T-cell therapy has emerged as a pivotal treatment modality.
Purpose of the Study:
- To review the current landscape of CAR T-cell therapy for multiple myeloma.
- To evaluate emerging therapies and novel targets in multiple myeloma treatment.
Main Methods:
- Literature review of CAR T-cell therapy in multiple myeloma.
- Analysis of recent clinical trial data and research.
- Discussion of future therapeutic directions and targets.
Main Results:
- CAR T-cell therapy has demonstrated significant efficacy in relapsed/refractory multiple myeloma.
- Ongoing research is exploring new CAR T-cell targets and strategies to overcome resistance.
- Several novel therapies are in development for multiple myeloma.
Conclusions:
- CAR T-cell therapy represents a major breakthrough in multiple myeloma treatment.
- Future research will focus on optimizing CAR T-cell therapy and exploring new targets to improve patient outcomes.
- The evolving therapeutic landscape offers new hope for patients with multiple myeloma.
